A group of consumers who purchased Nexium, a heartburn medication, in Massachusetts since March 2001 filed a class-action lawsuit against AstraZeneca. They claimed that the pharmaceutical company deceptively marketed the medication as superior to its other heartburn drugs so that consumers would buy the more expensive Nexium. In October 2012, AstraZeneca agreed to settle the lawsuit but the terms of the settlement have not yet been announced. (Commonwealth Care Alliance v. AstraZeneca Pharmaceuticals L.P., Case No. 05-0269)
MADISON, CONN. May 6, 2025 – U-Haul is engaged in a bait-and-switch pricing scheme with its $19.95 truck rental ads, according to an investigation by consumer advocacy organization truthinadvertising.org (TINA.org).…
TINA.org calls on regulators to stop moving company’s bait and switch.
Complaint alleges IML was a $1.2 billion scam.
What you should know about ingredient studies.
Will master resell rights actually give you the dream life?